DRG Market Assessment reports

Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of neuropathic back pain comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of CLBP for…

Clarivate Epidemiology’s coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of CLBP for…

Clarivate Epidemiology’s coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of CLBP for…

Clarivate Epidemiology’s coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of CLBP for…

Clarivate Epidemiology’s coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of CLBP for…

Amyotrophic lateral sclerosis (ALS) is a progressively debilitating disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of…

Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics…